Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Anesthesiology. 2018 May;128(5):921–931. doi: 10.1097/ALN.0000000000002038

Figure 6. Dexmedetomidine downregulates the circulating pro-inflammatory mediator leukotriene B4, (LTB4; A) and upregulates the circulating pro-resolving mediator lipoxin A4 (LXA4; B).

Figure 6.

Four groups of randomly-assigned mice (n=8/group) were administered saline vehicle (control), HMGB1 alone, HMGB1+ dexmedetomidine, or HMGB1 + dexmedetomidine + methyllycaconitine. Twenty-four hours later, mice were sacrificed and the blood was harvested and assayed by ELISA for plasma LTB4 (A) and LXA4 (B). Data are expressed as means ± SD fold-change relative to control and were analyzed by one-way ANOVA and Tukey post hoc test. * = P<0.0001 for comparisons shown.